Literature DB >> 28085744

An Unusual Pelvic Mass in a Pediatric Patient: A Case Report and Review of the Pathology.

Brent D Bauman1, Christopher L Moertel, Eugene Zheng, Amanda Louiselle, Elizabeth Berdan, David Berger, Bradley Segura.   

Abstract

INTRODUCTION: Neurofibromatosis type 1 (NF1) is the most commonly inherited autosomal dominant disorder in humans. NF1 patients have increased risk for gastrointestinal stromal tumors (GISTs). A Meckel's diverticulum (MD) represents a persistent embryonic omphalomesenteric duct characterized as a true diverticulum located near the ileocecal valve. We report a unique clinical case whereby a patient with NF1 developed a GIST within a MD. CASE: An adolescent male with NF1 presented with persistent lower abdominal pain. Clinical evaluation demonstrated a large pelvic mass. In the operating room, the mass was noted to emerge from a MD. Final pathology demonstrated a GIST with negative margins and CD117 positivity. DISCUSSION: Patients with NF1 are at increased risk for mesenchymal tumors including malignant peripheral nerve sheath tumors. GISTs are the most important and frequent non-neurological malignancy in NF1 and develop in ∼7% of NF1 patients. GISTs tend to be multifocal in NF1; however, they rarely occur within a Meckel's diverticula.
CONCLUSIONS: Our case represents a rare case of a patient with NF1 who developed a symptomatic GIST within a MD. We recommend utilizing laparoscopy to determine resectability and clarify the diagnosis in this unique patient population who are at risk for multiple neoplasms.

Entities:  

Mesh:

Year:  2017        PMID: 28085744     DOI: 10.1097/MPH.0000000000000773

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  1 in total

1.  Malignancy and Meckel's diverticulum: A systematic literature review and 14-year experience at a tertiary referral center.

Authors:  Kathleen van Malderen; Priya Vijayvargiya; Michael Camilleri; David W Larson; Robert Cima
Journal:  United European Gastroenterol J       Date:  2018-01-16       Impact factor: 4.623

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.